Dr. Philip McCarthy of Roswell Park Cancer Institute on transplants: best induction therapies, best approaches for high risk and how patients can recover faster
Dr.McCarthy shares his experience with transplantation and that transplant eligibility depends on fitness, and that older patients can complete transplants
Secondary Cancer Risks of Lenalidomide for Newly Diagnosed Myeloma Patients
I'm doing chemo and I have intense food cravings and aversions. Help!
Dr. Damian Green shares a new approach to combine two proven approaches (immunotherapy and radiation) to selectively target only active myeloma cells using the common CD38 protein
Dr. Damian Green shares a new approach to combine two proven approaches (immunotherapy and radiation)
Who should consider a donor (allo) transplant? Young, high-risk myeloma patients and patients with high relapse risk. Considering clinical trials as your first treatment option with Dr. Parmeswaran Hari.
Dr. Hari describes myeloma patients who are to benefit the most from allogeneic translpant
Shutting down myeloma growth by changing the soil where it grows with Dr. Noopur Raje of Massachusetts General Hospital Cancer Center
Myeloma cells can't survive outside of the bone marrow. Dr.Raje, tells us that the "soil" in which they are growing is an important target for new treatments.
What can you do when your myeloma medication is no longer working? Dr. Jatin Shah describes the best new approaches to overcome drug resistance and a host of treatment alternatives.
Dr. Shah describes his focus to overcome drug resistance and provide ways to use new therapies to expand the capacity of existing drugs
Are you confused by your myeloma labs? Dr. Michael Misialek says your pathologist is ready and willing to help decipher the results.
Dr. Michael Misialek reminds us that we have a pathologist that can help understand the confusing results we see on our lab work.
The path to personalized medicine: Dr. Gareth Morgan describes his work to subdivide myeloma into actionable types, target specific genes and pathways, and study the impact of the bone marrow environment
Dr. Gareth Morgan shares his approach to personalized medicine in multiple myeloma. He reiterates that myeloma is not a single disease, but a group of diseases.
What healthy foods can I eat when I'm neutropenic?
Weathering those panic attacks
I'm out of (wig) prison!
Dr. Rodger Tiedemann discusses why myeloma persistently returns and his work to strike at the root of the disease by targeting earlier stage progenitor cells
Dr. Rodger Tiedemann describes why proteasome inhibitors are useful to treat myeloma but will never be a cure for myeloma.
Dr. Rafael Fonseca of the Mayo Clinic Scottsdale discusses today's and tomorrow's myeloma genetic approaches
Dr. Rafael Fonseca describes his research focus on genetic markers for myeloma and how they can become predictors for disease type and progression.
Dr. Frits van Rhee of UAMS discusses Total Therapy, his approach to address high-risk patient needs, and the importance genetic and imaging tests and how these pinpoint prognosis and best treatment path options
Dr. Frits van Rhee shares how Total Therapy is modeled after the approach in childhood acute lymphoblastic leukemia that showed dramatic results.
Dr. Shaji Kumar of the Mayo Clinic discusses the road to personalized myeloma treatment and three approaches we can take today before targeted treatments become a clinic reality
Dr.Kumar discusses the unique opportunity we have with myeloma compared to other cancers where we can detect and potentially treat early.
Dr. Sergio Giralt of Memorial Sloan-Kettering discusses the role of transplant, how transplant side effects (including host vs. graft) are being minimized and how all roads to a cure lead through complete remission
Dr.Giralt discusses the role of transplant as consolidation therapy and his current study of how the various approaches relate to a patient's cytogenetics.
Dr. Craig Crews of the Crews Laboratory at Yale University describes his discovery and development of carfilzomib (Kyprolis) and what it takes to get a new drug across the
Dr. Craig Crews of the Crews Laboratory describes his discovery and development of carfilzomib.
Dr. James R. Berenson discusses his use of myeloma therapies in a variety of combinations to target myeloma but to also address quality of life issues
Dr. Berenson discusses his unique approach to use myeloma therapies in a variety of combinations
Dr. Bensinger discusses a wide variety of new approaches to treatment including monoclonal antibody studies, new oral proteasome inhibitor studies, combinations with and without transplants, and the pros and cons of allo vs. auto transplantation
Dr. William Bensinger reviews the many approaches at the Fred Hutchinson Cancer Research Center to both improve care and move towards a cure for myeloma.
Dr. Benson describes how immunotherapy and NK cells work, and why most cancers are genetic or molecular diseases and not anatomical diseases
Dr.Benson shares how NK cells combat myeloma and how this and other immunotherapy treatments work to use your own immune system to attack the myeloma cells.
Dr. Robert A. Kyle discusses the history of myeloma innovation and the key elements needed to drive towards a cure
Dr. Robert Kyle, a myeloma pioneer, gives a history of "Innovation in Myeloma."
Dr. C. Ola Landgren discusses the importance and availability of new, more accurate diagnostic testing, and his detailed work in MGUS and smoldering myeloma
Dr. Landgren teaches that new tests in flow cytometry are available that can detect minimal residual disease (MRD)
Dr. Don Benson discusses the benefits of participating in a clinical trial
Dr. Benson provides a solid foundation for understanding clinical trials, answers patients' common questions
